When good times go bad: managing ‘legal high’ complications in the emergency department

References

• Musselman ME, Hampton JP. “Not for human consumption”: a review of emerging designer drugs. Pharmacotherapy. 2014;34(7):745–757.
   PubMed Web of Science ®Google Scholar
• Esters of Morphine. In: UNODC, ed. United Nations; 1953:36–38.
   Google Scholar
• Thomas A, Nallur DG, Jones N, Deslandes PN. Diphenhydramine abuse and detoxification: a brief review and case report. J Psychopharmacol. 2009;23(1):101–105.
   PubMed Web of Science ®Google Scholar
• Dilsaver SC. Antimuscarinic agents as substances of abuse – a review. J Clin Psychopharm. 1988;8(1):14–22.
   PubMed Web of Science ®Google Scholar
• Glatstein M, Alabdulrazzaq F, Scolnik D. Belladonna Alkaloid Intoxication: the 10-year experience of a large tertiary care pediatric hospital. Am J Ther. 2016;23(1):e74–e77.
   PubMed Web of Science ®Google Scholar
• Diker D, Markovitz D, Rothman M, Sendovski U. Coma as a presenting sign of Datura stramonium seed tea poisoning. Eur J Intern Med. 2007;18(4):336–338.
   PubMed Web of Science ®Google Scholar
• Krenzelok EP. Aspects of Datura poisoning and treatment. Clin Toxicol (Phila). 2010;48(2):104–110.
   PubMed Web of Science ®Google Scholar
• Krenzelok EP, Jacobsen TD, Aronis JM. Jimsonweed (Datura stramonium) poisoning and abuse. J Toxicol Clin Toxicol. 1995;40:303–304.
   Google Scholar
• Feldman MD, Behar M. A case of massive diphenhydramine abuse and withdrawal from use of the drug. JAMA. 1986;255(22):3119–3120.
   PubMed Web of Science ®Google Scholar
• Crouch BI, Caravati EM, Booth J. Trends in child and teen nonprescription drug abuse reported to a regional poison control center. Am J Health-Syst Ph. 2004;61(12):1252–1257.
   PubMed Web of Science ®Google Scholar
• Wang GS, Monte A, Bagdure D, Heard K. Hepatic failure despite early acetylcysteine following large acetaminophen-diphenhydramine overdose. Pediatrics. 2011;127(4):e1077–e1080.
   PubMed Web of Science ®Google Scholar
• Koppel C, Ibe K, Tenczer J. Clinical symptomatology of diphenhydramine overdose: an evaluation of 136 cases in 1982 to 1985. J Toxicol Clin Toxicol. 1987;25(1–2):53–70.
   PubMed Web of Science ®Google Scholar
• Ramachandran K, Sirop P. Rare complications of diphenhydramine toxicity. Conn Med. 2008;72(2):79–82.
   PubMedGoogle Scholar
• Krenzelok EP, Anderson GM, Mirick M. Massive diphenhydramine overdose resulting in death. Ann Emerg Med. 1982;11(4):212–213.
   PubMed Web of Science ®Google Scholar
• Li K, Gugelmann H, Tabas JA. Ecg of the month. Ann Emerg Med. 2015;66(4):363.
   PubMed Web of Science ®Google Scholar
• Tomassoni AJ, Weisman RS. Antihistamines and Decongestants. Goldfrank’s Toxicologic Emergencies. 9th ed. New York, NY: McGraw Hill; 2011.
   Google Scholar
• Benowitz I, Cohen AR, Glykys JC, Gorstein SV, Burns MM, Miller ES. An Altered, Unresponsive Teenager in the Emergency Department. J Emerg Med. 2016;50(1):116–120.
   PubMed Web of Science ®Google Scholar
• Abdi A, Rose E, Levine M. Diphenhydramine overdose with intraventricular conduction delay treated with hypertonic sodium bicarbonate and i.v. lipid emulsion. West J Emerg Med. 2014;15(7):855–858.
   PubMedGoogle Scholar
• Quin GI, Fanning NF, Plunkett PK. Nutmeg intoxication. J Accid Emerg Med. 1998;15(4):287–288.
   PubMedGoogle Scholar
• Williams EY, West F. The use of nutmeg as a psychotrpic drug. Report of two cases. J Natl Med Assoc. 1968;60(4):289–290.
   PubMedGoogle Scholar
• Forrester MB. Nutmeg intoxication in Texas, 1998–2004. Hum Exp Toxicol. 2005;24(11):563–566.
   PubMed Web of Science ®Google Scholar
• Carstairs SD, Cantrell FL. The spice of life: an analysis of nutmeg exposures in California. Clin Toxicol (Phila). 2011;49(3):177–180.
   PubMed Web of Science ®Google Scholar
• Ehrenpreis JE, DesLauriers C, Lank P, Armstrong PK, Leikin JB. Nutmeg poisonings: a retrospective review of 10 years experience from the Illinois Poison Center, 2001–2011. J Med Toxicol. 2014;10(2):148–151.
   PubMedGoogle Scholar
• Halcomb S. Essential Oils. In: Nelson LS, Lewin NA, Howland MA, Hoffman RS, Goldfrank L, Flomenbaum N, editors. Goldfrank’s Toxicologic Emergencies. 9th ed. New York, NY: McGrawHill; 2011:1.
   Google Scholar
• Truitt EB Jr, Duritz G, Ebersberger EM. Evidence of monoamine oxidase inhibition by myristicin and nutmeg. Proc Soc Exp Biol Med. 1963;112:647–650.
   PubMed Web of Science ®Google Scholar
• Braun U, Kalbhen DA. Evidence for the biogenic formation of amphetamine derivatives from components of nutmeg. Pharmacology. 1973;9(5):312–316.
   PubMed Web of Science ®Google Scholar
• Ahmad A, Thompson HS. Nutmeg mydriasis. JAMA. 1975;234(3):274.
   PubMed Web of Science ®Google Scholar
• Michelot D, Melendez-Howell LM. Amanita muscaria: chemistry, biology, toxicology, and ethnomycology. Mycol Res. 2003;107(Pt 2):131–146.
   PubMedGoogle Scholar
• Goldfrank L. Mushrooms. In: Nelson LS, Lewin NA, Howland MA, Hoffman RS, Goldfrank L, Flomenbaum N, editors. Goldfrank’s Toxicologic Emergencies. 9th ed. New York, NY: McGrawHill; 2011:1528.
   Google Scholar
• Halpern JH. Hallucinogens and dissociative agents naturally growing in the United States. Pharmacol Ther. 2004;102(2):131–138.
   PubMed Web of Science ®Google Scholar
• Satora L, Pach D, Butryn B, Hydzik P, Balicka-Slusarczyk B. Fly agaric (Amanita muscaria) poisoning, case report and review. Toxicon. 2005;45(7):941–943.
   PubMed Web of Science ®Google Scholar
• Nelson LS, Juurlink DN, Perrone J. Addressing the opioid epidemic. JAMA. 2015;314(14):1453–1454.
   PubMed Web of Science ®Google Scholar
• Taibbi M. If kratom helps opioid addicts, why might DEA outlaw it?: PBS Newshour; 2017.
   Google Scholar
• MacDonald R, Heiner J, Villarreal J, Strote J. Loperamide dependence and abuse. BMJ Case Rep. 2015;2015.
   Google Scholar
• Miller H, Panahi L, Tapia D, Tran A, Bowman JD. Loperamide misuse and abuse. J Am Pharm Assoc (2003). 2017;57(2S):S45–S50.
   PubMedGoogle Scholar
• Daniulaityte R, Carlson R, Falck R, et al. “I just wanted to tell you that loperamide WILL WORK”: a web-based study of extra-medical use of loperamide. Drug Alcohol Depend. 2013;130(1–3):241–244.
   PubMed Web of Science ®Google Scholar
• Wu PE, Juurlink DN. Clinical review: loperamide toxicity. Ann Emerg Med. 2017;70(2):245–252.
   PubMed Web of Science ®Google Scholar
• Swank KA, Wu E, Kortepeter C, McAninch J, Levin RL. Adverse event detection using the FDA post-marketing drug safety surveillance system: cardiotoxicity associated with loperamide abuse and misuse. J Am Pharm Assoc (2003). 2017;57(2S):S63–S67.
   PubMedGoogle Scholar
• Pelders MG, Ros JJ. Poppy seeds: differences in morphine and codeine content and variation in inter- and intra-individual excretion. J Forensic Sci. 1996;41(2):209–212.
   PubMed Web of Science ®Google Scholar
• Braye K, Harwood T, Inder R, Beasley R, Robinson G. Poppy seed tea and opiate abuse in New Zealand. Drug Alcohol Rev. 2007;26(2):215–219.
   PubMed Web of Science ®Google Scholar
• Bailey K, Richards-Waugh L, Clay D, Gebhardt M, Mahmoud H, Kraner JC. Fatality involving the ingestion of phenazepam and poppy seed tea. J Anal Toxicol. 2010;34(8):527–532.
   PubMed Web of Science ®Google Scholar
• Nanjayya SB, Murthy P, Chand PK, et al. A case of poppy tea dependence in an octogenarian lady. Drug Alcohol Rev. 2010;29(2):216–218.
   PubMed Web of Science ®Google Scholar
• Prozialeck WC. Update on the pharmacology and legal status of Kratom. J Am Osteopath Assoc. 2016;116(12):802–809.
   PubMed Web of Science ®Google Scholar
• Fluyau D, Revadigar N. Biochemical benefits, diagnosis, and clinical risks evaluation of Kratom. Front Psychiatry. 2017;8:62.
   PubMed Web of Science ®Google Scholar
• Kelly D. Lifesaving medicine or deadly drug?; Kratom, a plant used to treat addiction, gets a reprieve from DEA. Los Angeles Times. 2016 [October 20]; A8. Available from: https://www.pressreader.com/usa/los-angeles-times/20161020/281625304835034. Accessed May 15, 2017.
   Google Scholar
• Suwanlert S. A study of kratom eaters in Thailand. Bull Narc. 1975;27(3):21–27.
   PubMedGoogle Scholar
• Babu KM, McCurdy CR, Boyer EW. Opioid receptors and legal highs: Salvia divinorum and Kratom. Clin Toxicol (Phila). 2008;46(2):146–152.
   PubMed Web of Science ®Google Scholar
• Kronstrand R, Roman M, Thelander G, Eriksson A. Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend Krypton. J Anal Toxicol. 2011;35(4):242–247.
   PubMed Web of Science ®Google Scholar
• Neerman MF, Frost RE, Deking J. A drug fatality involving Kratom. J Forensic Sci. 2013;58 (Suppl 1):S278–S279.
   PubMed Web of Science ®Google Scholar
• McIntyre IM, Trochta A, Stolberg S, Campman SC. Mitragynine ‘Kratom’ related fatality: a case report with postmortem concentrations. J Anal Toxicol. 2015;39(2):152–155.
   PubMed Web of Science ®Google Scholar
• Helander A, Backberg M, Beck O. MT-45, a new psychoactive substance associated with hearing loss and unconsciousness. Clin Toxicol (Phila). 2014;52(8):901–904.
   PubMed Web of Science ®Google Scholar
• Siddiqi S, Verney C, Dargan P, Wood DM. Understanding the availability, prevalence of use, desired effects, acute toxicity and dependence potential of the novel opioid MT-45. Clin Toxicol (Phila). 2015;53(1):54–59.
   PubMed Web of Science ®Google Scholar
• Lozier MJ, Boyd M, Stanley C, et al. Acetyl fentanyl, a novel fentanyl analog, causes 14 overdose deaths in rhode island, March-May 2013. J Med Toxicol. 2015;11(2):208–217.
   PubMed Web of Science ®Google Scholar
• Drug Enforcement Administration DoJ. Emerging Threat Report: 2016 Report. In: Laboratory STaR, ed; 2017.
   Google Scholar
• Schumann H, Erickson T, Thompson TM, Zautcke JL, Denton JS. Fentanyl epidemic in Chicago, Illinois and surrounding Cook County. Clin Toxicol (Phila). 2008;46(6):501–506.
   PubMed Web of Science ®Google Scholar
• Valente MJ, Guedes de Pinho P, de Lourdes Bastos M, Carvalho F, Carvalho M. Khat and synthetic cathinones: a review. Arch Toxicol. 2014;88(1):15–45.
   PubMed Web of Science ®Google Scholar
• Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol. 2012;8(1):33–42.
   PubMedGoogle Scholar
• American Association of Poison Control Centers. Bath Salts Data. 2016 March 31. Available from: https://aapcc.s3.amazonaws.com/files/library/Bath_Salts_Web_Data_through_3.2016.pdf. Accessed May 15, 2017.
   Google Scholar
• Drug Enforcement Administration, DoJ. Schedules of controlled substances: placement of 10 synthetic cathinones into schedule I. Final rule. Fed Regist. 2017;82(39):12171–12177.
   Google Scholar
• Nugteren-van Lonkhuyzen JJ, van Riel AJ, Brunt TM, Hondebrink L. Pharmacokinetics, pharmacodynamics and toxicology of new psychoactive substances (NPS): 2C-B, 4-fluoroamphetamine and benzofurans. Drug Alcohol Depend. 2015;157:18–27.
   PubMed Web of Science ®Google Scholar
• Zawilska JB, Andrzejczak D. Next generation of novel psychoactive substances on the horizon – A complex problem to face. Drug Alcohol Depend. 2015;157:1–17.
   PubMed Web of Science ®Google Scholar
• Hofer KE, Faber K, Muller DM, et al. Acute toxicity associated with the recreational use of the novel psychoactive benzofuran N-methyl-5-(2 aminopropyl)benzofuran. Ann Emerg Med. 2017;69(1):79–82.
   PubMed Web of Science ®Google Scholar
• Corazza O, Schifano F, Farre M, et al. Designer drugs on the internet: a phenomenon out-of-control? the emergence of hallucinogenic drug Bromo-Dragonfly. Curr Clin Pharmacol. 2011;6(2):125–129.
   PubMedGoogle Scholar
• Coppola M, Mondola R. Bromo-DragonFly: chemistry, pharmacology and toxicology of a Benzodifuran derivative producing LSD-like effects. J Add Res Ther. 2012;3(4):133.
   Google Scholar
• Chavarin A, Nogue S, Castaneda-Pomeda M, Gil V. The dangers of buying “research chemicals” online, bromo-dragonfly mislabelled as 2C-B Fly: a confirmed case report, and its follow up in “research chemical” specific social media. Clin Toxicol. 2013;51(4):347–347.
   Web of Science ®Google Scholar
• Wood DM, Looker JJ, Shaikh L, et al. Delayed onset of seizures and toxicity associated with recreational use of Bromo-dragonFLY. J Med Toxicol. 2009;5(4):226–229.
   PubMedGoogle Scholar
• Personae M, Hulten P. Bromo-Dragonfly, a life threatening designer drug. Clin Toxicol. 2008;46(5):379–380.
   Web of Science ®Google Scholar
• Andreasen MF, Telving R, Birkler RI, Schumacher B, Johannsen M. A fatal poisoning involving Bromo-Dragonfly. Forensic Sci Int. 2009;183(1–3):91–96.
   PubMed Web of Science ®Google Scholar
• Liggett SB. Propylhexedrine Intoxication: clinical presentation and pharmacology. South Med J. 1982;75(2):250–251.
   PubMed Web of Science ®Google Scholar
• Anderson RJ, Garza HR, Garriott JC, Dimaio V. Intravenous propylhexedrine (Benzedrex) abuse and sudden-death. Am J Med. 1979;67(1):15–20.
   PubMed Web of Science ®Google Scholar
• Fernandez Julia P, Francis EM. Propylhexedrine: a vintage drug of abuse, rediscovered. J Psychoactive Drugs. 2012;44(3):277–279.
   PubMed Web of Science ®Google Scholar
• Marsden P, Sheldon J. Acute poisoning by propylhexedrine. Br Med J. 1972;1(5802):730.
   PubMedGoogle Scholar
• Fornazzari L, Carlen PL, Kapur BM. Intravenous abuse of propylhexedrine (Benzedrex) and the risk of brainstem dysfunction in young adults. Can J Neurol Sci. 1986;13(4):337–339.
   PubMed Web of Science ®Google Scholar
• White L, DiMaio VJ. Intravenous propylhexedrine and sudden death. N Engl J Med. 1977;297(19):1071.
   PubMed Web of Science ®Google Scholar
• Carstairs SD, Cantrell FL. Peyote and mescaline exposures: a 12-year review of a statewide poison center database. Clin Toxicol (Phila). 2010;48(4):350–353.
   PubMed Web of Science ®Google Scholar
• Mowry JB, Spyker DA, Brooks DE, Zimmerman A, Schauben JL. 2015 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 33rd Annual Report. Clin Toxicol (Phila). 2016;54(10):924–1109.
   PubMed Web of Science ®Google Scholar
• Teitelbaum DT, Wingeleth DC. Diagnosis and management of recreational mescaline self poisoning. J Analytical Toxicol. 1977;1(1):36–37.
   Web of Science ®Google Scholar
• Administration DE. Schedules of controlled substances: placement of Ketamine into schedule III. In: Justice Do, ed1999.
   Google Scholar
• Winstock AR, Lawn W, Deluca P, Borschmann R. Methoxetamine: an early report on the motivations for use, effect profile and prevalence of use in a UK clubbing sample. Drug Alcohol Rev. 2016;35(2):212–217.
   PubMed Web of Science ®Google Scholar
• Backberg M, Beck O, Helander A. Phencyclidine analog use in Sweden-intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project. Clin Toxicol. 2015;53(9):856–864.
   PubMed Web of Science ®Google Scholar
• Elliott SP, Brandt SD, Wallach J, Morris H, Kavanagh PV. First reported fatalities associated with the ‘research chemical’ 2-methoxydiphenidine. J Anal Toxicol. 2015;39(4):287–293.
   PubMed Web of Science ®Google Scholar
• Wallach J, Kang H, Colestock T, et al. Pharmacological Investigations of the Dissociative ‘Legal Highs’ Diphenidine, Methoxphenidine and Analogs. PLoS One. 2016;11(6):e0157021.
   PubMed Web of Science ®Google Scholar
• Adamowicz P, Zuba D. Fatal intoxication with methoxetamine. J Forensic Sci. 2015;60 (Suppl 1):S264–S268.
   PubMedGoogle Scholar
• Helander A, Beck O, Backberg M. Intoxications by the dissociative new psychoactive substances diphenidine and methoxphenidine. Clin Toxicol (Phila). 2015;53(5):446–453.
   PubMed Web of Science ®Google Scholar
• Zawilska JB. Methoxetamine–a novel recreational drug with potent hallucinogenic properties. Toxicol Lett. 2014;230(3):402–407.
   PubMed Web of Science ®Google Scholar
• Majlesi N, Lee DC, Ali SS. Dextromethorphan abuse masquerading as a recurrent seizure disorder. Pediatr Emerg Care. 2011;27(3):210–211.
   PubMed Web of Science ®Google Scholar
• Shafi H, Imran M, Usman HF, et al. Deaths due to abuse of dextromethorphan sold over-the-counter in Pakistan. Egypt J Forensic Sci. 2016;6(3):280–283.
   Google Scholar
• Dextromethorphan (DXM); 2017. Available from: http://www.cesar.umd.edu/cesar/drugs/dxm.asp#history. Accessed April 20, 2017.
   Google Scholar
• Chyka PA, Erdman AR, Manoguerra AS, et al. Dextromethorphan poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007;45(6):662–677.
   PubMed Web of Science ®Google Scholar
• Stanciu CN, Penders TM, Rouse EM. Recreational use of dextromethorphan, “Robotripping”-A brief review. Am J Addict. 2016;25(5):374–377.
   PubMed Web of Science ®Google Scholar
• Cunningham V. Dextromethorphan abuse in teens: beware acetaminophen poisoning! CJEM. 2011;13(5):298.
   PubMedGoogle Scholar
• Justice UDo. Intelligence Bulletin: DXM (Dextromethorphan); 2004. Avaialble from: https://www.justice.gov/archive/ndic/pubs11/11,563/. Accessed April 20, 2017.
   Google Scholar
• Hendrickson RG, Cloutier RL. “Crystal dex:” free-base dextromethorphan. J Emerg Med. 2007;32(4):393–396.
   PubMed Web of Science ®Google Scholar
• Boyer EW. Dextromethorphan abuse. Pediatr Emerg Care. 2004;20(12):858–863.
   PubMed Web of Science ®Google Scholar
• Schneider SM, Michelson EA, Boucek CD, Ilkhanipour K. Dextromethorphan poisoning reversed by naloxone. Am J Emerg Med. 1991;9(3):237–238.
   PubMed Web of Science ®Google Scholar
• Antoniou T, Juurlink DN. Dextromethorphan abuse. CMAJ. 2014;186(16):E631.
   PubMed Web of Science ®Google Scholar
• Wolfe TR, Caravati EM. Massive dextromethorphan ingestion and abuse. Am J Emerg Med. 1995;13(2):174–176.
   PubMed Web of Science ®Google Scholar
• Ng YY, Lin WL, Chen TW, et al. Spurious hyperchloremia and decreased anion gap in a patient with dextromethorphan bromide. Am J Nephrol. 1992;12(4):268–270.
   PubMed Web of Science ®Google Scholar
• Hung YM. Bromide intoxication by the combination of bromide-containing over-the-counter drug and dextromethorphan hydrobromide. Hum Exp Toxicol. 2003;22(8):459–461.
   PubMed Web of Science ®Google Scholar
• Babu KM. Hallucinogens. In: Nelson LS, Lewin NA, Howland MA, Hoffman RS, Goldfrank L, Flomenbaum N, editors. Goldfrank’s Toxicologic Emergencies. 9th ed. New York, NY: McGraw Hill; 2011.
   Google Scholar
• Prisinzano TE. Psychopharmacology of the hallucinogenic sage Salvia divinorum. Life Sci. 2005;78(5):527–531.
   PubMed Web of Science ®Google Scholar
• Sheffler DJ, Roth BL. Salvinorin A: the “magic mint” hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci. 2003;24(3):107–109.
   PubMed Web of Science ®Google Scholar
• Albertson DN, Grubbs LE. Subjective effects of Salvia divinorum: LSD- or marijuana-like? J Psychoactive Drugs. 2009;41(3):213–217.
   PubMed Web of Science ®Google Scholar
• Johnson LA, Johnson RL, Portier RB. Current “legal highs”. J Emerg Med. 2013;44(6):1108–1115.
   PubMed Web of Science ®Google Scholar
• Vohra R, Seefeld A, Cantrell FL, Clark RF. Salvia divinorum: exposures reported to a statewide poison control system over 10 years. J Emerg Med. 2011;40(6):643–650.
   PubMed Web of Science ®Google Scholar
• Richardson WH, 3rd, Slone CM, Michels JE. Herbal drugs of abuse: an emerging problem. Emerg Med Clin North Am. 2007;25(2):435–457.
   PubMed Web of Science ®Google Scholar
• Juszczak GR, Swiergiel AH. Recreational use of D-Lysergamide from the seeds of Argyreia nervosa, Ipomoea tricolor, Ipomoea violacea, and Ipomoea purpurea in Poland. J Psychoactive Drugs. 2013;45(1):79–93.
   PubMed Web of Science ®Google Scholar
• Klinke HB, Muller IB, Steffenrud S, Dahl-Sorensen R. Two cases of lysergamide intoxication by ingestion of seeds from Hawaiian Baby Woodrose. Forensic Sci Int. 2010;197(1–3):E1–E5.
   PubMed Web of Science ®Google Scholar
• Nelson ME, Bryant SM, Aks SE. Emerging drugs of abuse. Dm-Dis Mon. 2014;60(3):110–132.
   PubMed Web of Science ®Google Scholar
• Trecki J, Gerona RR, Schwartz MD. Synthetic cannabinoid-related illnesses and deaths. N Engl J Med. 2015;373(2):103–107.
   PubMed Web of Science ®Google Scholar
• Drug Enforcement Administration DoJ. Schedules of Controlled Substances: Temporary Placement of Six Synthetic Cannabinoids (5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA) into Schedule I. Temporary Scheduling Order. Fed Regist. 2017;82(67):17119–17124.
   PubMedGoogle Scholar
• Baumeister D, Tojo LM, Tracy DK. Legal highs: staying on top of the flood of novel psychoactive substances. Ther Adv Psychopharmacol. 2015;5(2):97–132.
   PubMed Web of Science ®Google Scholar
• Winstock A, Lynskey M, Borschmann R, Waldron J. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample. J Psychopharmacol. 2015;29(6):698–703.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Santacroce R, Papanti D, Elgharably Y, Prilutskaya M, Corazza O. Synthetic Cannabinoids: psychopharmacology, clinical aspects, and psy-chotic onset. CNS Neurol Disord Drug Targets. 2017;16(5):567–575.
   PubMed Web of Science ®Google Scholar
• Phillips J, Lim F, Hsu R. The emerging threat of synthetic cannabinoids. Nurs Manage. 2017;48(3):22–30.
   PubMedGoogle Scholar
• Patel NA, Jerry JM, Jimenez XF, Hantus ST. New-Onset Refractory Status Epilepticus Associated With the Use of Synthetic Cannabinoids. Psychosomatics. 2017;58(2):180–186.
   PubMed Web of Science ®Google Scholar
• Raheemullah A, Laurence TN. Repeated thrombosis after synthetic cannabinoid use. J Emerg Med. 2016;51(5):540–543.
   PubMed Web of Science ®Google Scholar
• Cunningham N. Hallucinogenic plants of abuse. Emerg Med Australas. 2008;20(2):167–174.
   PubMed Web of Science ®Google Scholar
• Riba J, Valle M, Urbano G, Yritia M, Morte A, Barbanoj MJ. Human pharmacology of ayahuasca: Subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther. 2003;306(1):73–83.
   PubMed Web of Science ®Google Scholar
• Heise CW, Brooks DE. Ayahuasca exposure: descriptive analysis of calls to US poison control centers from 2005 to 2015. J Med Toxicol. Epub 2016 Nov 28.
   Google Scholar
• dos Santos RG. A critical evaluation of reports associating ayahuasca with life-threatening adverse reactions. J Psychoactive Drugs. 2013;45(2):179–188.
   PubMed Web of Science ®Google Scholar
• Kava. In: Drug Enforcement Administration DoJ, editor. Washington, DC; 2013.
   Google Scholar
• Fu PP, Xia Q, Guo L, Yu H, Chan PC. Toxicity of kava kava. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2008;26(1):89–112.
   PubMed Web of Science ®Google Scholar
• Sarris J, LaPorte E, Schweitzer I. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiatry. 2011;45(1):27–35.
   PubMed Web of Science ®Google Scholar
• Bent S, Tiedt TN, Odden MC, Shlipak MG. The relative safety of ephedra compared with other herbal products. Ann Intern Med. 2003;138(6):468–471.
   PubMed Web of Science ®Google Scholar
• Lai MW, Klein-Schwartz W, Rodgers GC, et al. 2005 Annual Report of the American Association of Poison Control Centers’ national poisoning and exposure database. Clin Toxicol (Phila). 2006;44(6–7):803–932.
   PubMed Web of Science ®Google Scholar
• Dennehy CE, Tsourounis C, Horn AJ. Dietary supplement-related adverse events reported to the California Poison Control System. Am J Health Syst Pharm. 2005;62(14):1476–1482.
   PubMed Web of Science ®Google Scholar
• Wheatley D. Stress-induced insomnia treated with kava and valerian: singly and in combination. Hum Psychopharmacol. 2001;16(4):353–356.
   PubMed Web of Science ®Google Scholar
• Perez J, Holmes JF. Altered mental status and ataxia secondary to acute Kava ingestion. J Emerg Med. 2005;28(1):49–51.
   PubMed Web of Science ®Google Scholar
• Schelosky L, Raffauf C, Jendroska K, Poewe W. Kava and dopamine antagonism. J Neurol Neurosurg Psychiatry. 1995;58(5):639–640.
   PubMed Web of Science ®Google Scholar
• Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med. 1996;125(11):940–941.
   PubMed Web of Science ®Google Scholar
• Foo H, Lemon J. Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performance. Drug Alcohol Rev. 1997;16(2):147–155.
   PubMed Web of Science ®Google Scholar
• Teschke R, Schwarzenboeck A, Hennermann KH. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol. 2008;20(12):1182–1193.
   PubMed Web of Science ®Google Scholar
• Cairney S, Maruff P, Clough AR, Collie A, Currie J, Currie BJ. Saccade and cognitive impairment associated with kava intoxication. Hum Psychopharmacol. 2003;18(7):525–533.
   PubMed Web of Science ®Google Scholar
• Hannam S, Murray M, Romani L, Tuicakau M, M JW. Kava dermopathy in Fiji: an acquired ichthyosis? Int J Dermatol. 2014;53(12):1490–1494.
   PubMed Web of Science ®Google Scholar
• Long H. Inhalants. Goldfrank’s Toxicologic Emergencies. 9th ed. New York, NY: McGraw-Hill Companies; 2011:1187–1194.
   Google Scholar
• Marsolek MR, White NC, Litovitz TL. Inhalant abuse: monitoring trends by using poison control data, 1993–2008. Pediatrics. 2010;125(5):906–913.
   PubMed Web of Science ®Google Scholar
• van Amsterdam J, Nabben T, van den Brink W. Recreational nitrous oxide use: Prevalence and risks. Regul Toxicol Pharmacol. 2015;73(3):790–796.
   PubMed Web of Science ®Google Scholar
• Kurtzman TL, Otsuka KN, Wahl RA. Inhalant abuse by adolescents. J Adolesc Health. 2001;28(3):170–180.
   PubMed Web of Science ®Google Scholar
• Plumb J, Thomas RG. Sudden severe perioral swelling in an adolescent boy. Clin Toxicol (Phila). 2013;51(4):379–380.
   PubMed Web of Science ®Google Scholar
• Kopec KT, Brent J, Banner W, Ruha AM, Leikin JB. Management of cardiac dysrhythmias following hydrocarbon abuse: clinical toxicology teaching case from NACCT acute and intensive care symposium. Clin Toxicol (Phila). 2014;52(2):141–145.
   Google Scholar
• Cates AL, Cook MD. Severe Cardiomyopathy after Huffing Dust-Off. Case Rep Emerg Med. 2016;2016:9204790.
   PubMedGoogle Scholar
• Camara-Lemarroy CR, Rodriguez-Gutierrez R, Monreal-Robles R, Gonzalez-Gonzalez JG. Acute toluene intoxication–clinical presentation, management and prognosis: a prospective observational study. BMC Emerg Med. 2015;15:19.
   PubMedGoogle Scholar
• Dinsfriend W, Rao K, Matulevicius S. Inhalant-abuse myocarditis diagnosed by cardiac magnetic resonance. Tex Heart Inst J. 2016;43(3):246–248.
   PubMed Web of Science ®Google Scholar
• Thompson AG, Leite MI, Lunn MP, Bennett DL. Whippits, nitrous oxide and the dangers of legal highs. Pract Neurol. 2015;15(3):207–209.
   PubMedGoogle Scholar
• Kaar SJ, Ferris J, Waldron J, Devaney M, Ramsey J, Winstock AR. Up: The rise of nitrous oxide abuse. An international survey of contemporary nitrous oxide use. J Psychopharmacol. 2016;30(4):395–401.
   PubMed Web of Science ®Google Scholar
• Galbis-Reig D. A case report of kratom addiction and withdrawal. WMJ. 2016;115(1):49–52.
   PubMedGoogle Scholar